Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies

被引:7
|
作者
Zhu, Ni [1 ]
Xiao, Haowen [1 ,2 ]
Wang, Li-Mengmeng [1 ]
Fu, Shan [1 ]
Zhao, Chan [3 ]
Huang, He [1 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou 310003, Zhejiang, Peoples R China
[2] Guangzhou Liuhuaqiao Hosp, Dept Haematol, Guangzhou, Guangdong, Peoples R China
[3] Jinhua Cent Hosp, Dept Paediat, Jinhua, Zhejiang, Peoples R China
基金
中国国家自然科学基金; 国家高技术研究发展计划(863计划);
关键词
genetic alterations; hematologic malignancies; protein tyrosine kinases; protein tyrosine phosphatases; target therapy; ACUTE MYELOID-LEUKEMIA; FACTOR RECEPTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; CELL MYELOPROLIFERATIVE DISORDER; RISK MYELODYSPLASTIC SYNDROME; ACUTE LYMPHOBLASTIC-LEUKEMIA; FIP1L1-PDGFRA FUSION GENE; SOMATIC PTPN11 MUTATIONS;
D O I
10.2217/fon.14.280
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Protein tyrosine kinases and protein tyrosine phosphatases play pivotal roles in regulation of cellular phosphorylation and signal transduction with opposite functions. Accumulating evidences have uncovered the relevance of genetic alterations in these two family members to hematologic malignancies. This review underlines progress in understanding the pathogenesis of these genetic alterations including mutations and aberrant expression and the evolving protein tyrosine kinases and protein tyrosine phosphatases targeted therapeutic strategies in hematologic neoplasms.
引用
收藏
页码:659 / 673
页数:15
相关论文
共 50 条
  • [1] Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy
    Rada, Miran
    Qusairy, Zahraa
    Massip-Salcedo, Marta
    Macip, Salvador
    MOLECULAR CANCER RESEARCH, 2021, 19 (04) : 549 - 554
  • [2] Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies
    Verma, Dushyant
    Kantarjian, Hagop M.
    Rios, Mary Beth
    O'Brien, Susan
    Ault, Pat
    Burton, Elizabeth M.
    Estrov, Zeev
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 740 - 741
  • [3] Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
    Verma, Dushyant
    Kantarjian, Hagop
    Strom, Sara S.
    Rios, Mary Beth
    Jabbour, Elias
    Quintas-Cardama, Alfonso
    Verstovsek, Srdan
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2011, 118 (16) : 4353 - 4358
  • [4] Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review
    Salter, Brittany
    Burns, Ian
    Fuller, Katherine
    Eshaghpour, Ali
    Lionel, Anath C.
    Crowther, Mark
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 166 - 181
  • [5] Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology
    Holden, Joseph A.
    Willmore-Payne, Carlynn
    Layfield, Lester J.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2008, 85 (01) : 68 - 75
  • [6] Receptor protein tyrosine phosphatase ζ as a therapeutic target for glioblastoma therapy
    Müller, S
    Lamszus, K
    Nikolich, K
    Westphal, M
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (03) : 211 - 220
  • [7] Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies
    Jin, Feng
    Yin, Ming
    Mandava, Vinay
    Edlund, Helena
    Andrew, Marilee
    Patel, Priti
    Masson, Eric
    Al-Huniti, Nidal
    Wang, Xiaolin
    Slatter, J. Greg
    BLOOD, 2017, 130
  • [8] Regulation of ROMK channels by protein tyrosine kinase and tyrosine phosphatase
    Wang, WH
    Lin, DH
    Sterling, H
    TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (03) : 138 - 142
  • [9] Tyrosine kinase inhibitors in myeloid malignancies
    Burnett, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 21 - 21
  • [10] Tyrosine kinase inhibitors in pediatric malignancies
    Skolnik, Jeffrey M.
    Adamson, Peter C.
    CANCER INVESTIGATION, 2007, 25 (07) : 606 - 612